Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes
Seungah Lee, Dong Yun Lee
Ann Pediatr Endocrinol Metab. 2017;22(1):15-26.   Published online 2017 Mar 31     DOI: https://doi.org/10.6065/apem.2017.22.1.15
Citations to this article as recorded by Crossref logo
Obesidad y diabetes mellitus tipo 2: también unidas en opciones terapéuticas
Matilde Rubio-Almanza, Rosa Cámara-Gómez, Juan Francisco Merino-Torres
Endocrinología, Diabetes y Nutrición.2019; 66(3): 140.     CrossRef
Narrative review of the effects of antidiabetic drugs on albuminuria
Habib Yaribeygi, Stephen L. Atkin, Niki Katsiki, Amirhossein Sahebkar
Journal of Cellular Physiology.2019; 234(5): 5786.     CrossRef
Anti-inflammatory and pro-healing impacts of exendin-4 treatment in Zucker diabetic rats: Effects on skin wound fibroblasts
Monika Wolak, Teresa Staszewska, Marlena Juszczak, Małgorzata Gałdyszyńska, Ewa Bojanowska
European Journal of Pharmacology.2019; 842: 262.     CrossRef
Does obesity cause type 2 diabetes mellitus (T2DM)? Or is it the opposite?
John I. Malone, Barbara C. Hansen
Pediatric Diabetes.2019; 20(1): 5.     CrossRef
Obesity and type 2 diabetes: Also linked in therapeutic options
Matilde Rubio-Almanza, Rosa Cámara-Gómez, Juan Francisco Merino-Torres
Endocrinología, Diabetes y Nutrición (English ed.).2019; 66(3): 140.     CrossRef
GLP-1 Receptor in Pancreatic α-Cells Regulates Glucagon Secretion in a Glucose-Dependent Bidirectional Manner
Yanqing Zhang, Keshab R. Parajuli, Genevieve E. Fava, Rajesh Gupta, Weiwei Xu, Lauren U. Nguyen, Anadil F. Zakaria, Vivian A. Fonseca, Hongjun Wang, Franck Mauvais-Jarvis, Kyle W. Sloop, Hongju Wu
Diabetes.2019; 68(1): 34.     CrossRef
Exenatide extended-release pre-filled pen (Bydureon® BCise®): a profile of its use
Emma D. Deeks
Drugs & Therapy Perspectives.2019; 35(2): 51.     CrossRef
Feasibility, Adherence and Efficacy of Liraglutide Treatment in a Sample of Individuals With Mood Disorders and Obesity
Alessandro Cuomo, Simone Bolognesi, Arianna Goracci, Cristina Ciuoli, Bruno Beccarini Crescenzi, Giuseppe Maina, Gianluca Rosso, Edvige Facchi, Carla Maccora, Nicola Giordano, Valeria Verdino, Andrea Fagiolini
Frontiers in Psychiatry.2019;[Epub]     CrossRef
Treatment patterns, glycemic control & bodyweight with canagliflozin 300 mg versus GLP1RAs in Type II diabetes patients
Craig I Coleman, Shivani Pandya, Li Wang, Onur Baser, Jennifer Cai, Mike Ingham, Brahim Bookhart
Journal of Comparative Effectiveness Research.2019;[Epub]     CrossRef
Neuroprotective Effects of Brain-Gut Peptides: A Potential Therapy for Parkinson’s Disease
Dong Dong, Junxia Xie, Jun Wang
Neuroscience Bulletin.2019;[Epub]     CrossRef
Glutazumab, a novel long-lasting GLP-1/anti-GLP-1R antibody fusion protein, exerts anti-diabetic effects through targeting dual receptor binding sites
Caina Li, Miaomiao Yang, Xiaofeng Wang, Hua Zhang, Chenjiang Yao, Sujuan Sun, Quan Liu, Hao Pan, Shuainan Liu, Yi Huan, Shengnan Li, Jun Cao, Xing Wang, Yong Guo, Nan Guo, Shuqian Jing, Cheng Zhang, Zhufang Shen
Biochemical Pharmacology.2018; 150: 46.     CrossRef
Chrysophanol Relieves Cognition Deficits and Neuronal Loss Through Inhibition of Inflammation in Diabetic Mice
Xu Chu, Shuhu Zhou, Ran Sun, Lin Wang, Chunye Xing, Ruqing Liang, Qingxia Kong
Neurochemical Research.2018; 43(4): 972.     CrossRef
Glycemic Efficacy, Weight Effects, and Safety of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists
Yehuda Handelsman, Kathleen Wyne, Anthony Cannon, Michael Shannon, Doron Schneider
Journal of Managed Care & Specialty Pharmacy.2018; 24(9-a Suppl): S14.     CrossRef
Cardiovascular Outcomes with Once-Weekly GLP-1 RAs: Clinical and Economic Implications
Michael Heile, Kathleen Wyne, Liana K. Billings, Anthony Cannon, Yehuda Handelsman, Michael Shannon
Journal of Managed Care & Specialty Pharmacy.2018; 24(9-a Suppl): S42.     CrossRef